455 — Tianda Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$387.01m
- HK$428.59m
- HK$329.94m
Annual income statement for Tianda Pharmaceuticals, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 491 | 474 | 510 | 532 | 330 |
| Cost of Revenue | |||||
| Gross Profit | 361 | 259 | 241 | 256 | 152 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 475 | 501 | 537 | 553 | 379 |
| Operating Profit | 16.3 | -26.9 | -27.3 | -20.7 | -49.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 15.9 | -27.4 | -28 | -25.7 | -54.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 8.8 | -25.9 | -21.7 | -25 | -61.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 3.14 | -27.1 | -19.8 | -24.2 | -61.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3.14 | -27.1 | -19.8 | -24.2 | -61.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.002 | -0.013 | -0.012 | -0.011 | -0.029 |
| Dividends per Share | |||||
| Special Dividends per Share |